Synthetic Genomics Acquires IP from Febit | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic Genomics today announced its acquisition of the worldwide rights to three families of patents and patent applications related to synthetic genomic technologies from Germany's Febit Holding.

Included in the deal are related know-how, equipment, and technical support for implementation, La Jolla, Calif.-based Synthetic Genomics said. Financial terms of the transaction were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.